{
  "id": "d0f77014e0bddfe5",
  "title": "Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA",
  "description": "ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International\r\n\u00a0(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization\u2026",
  "content": "ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International\r\n\u00a0(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company\u2026 [+9772 chars]",
  "source": "GlobeNewswire",
  "source_url": "https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html",
  "published_at": "2025-12-05T00:00:00Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "geopolitics_security",
  "subcategory": null,
  "keywords": [
    "fda",
    "china",
    "search:drug approval FDA breakthrough"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "GlobeNewswire"
    },
    "author": "ASCENTAGE PHARMA GROUP INTERNATIONAL",
    "title": "Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA",
    "description": "ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International\r\n\u00a0(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization\u2026",
    "url": "https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html",
    "urlToImage": "https://ml.globenewswire.com/Resource/Download/b9623a51-a13b-4b80-8152-61d5014f4a0a",
    "publishedAt": "2025-12-05T00:00:00Z",
    "content": "ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International\r\n\u00a0(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company\u2026 [+9772 chars]"
  }
}